Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIV [clinicaltrials:NCT00006145]

Bio2RDF uri

Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIV [clinicaltrials:NCT00006145]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT00006145

Bio2RDF identifier

NCT00006145

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00006145

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00006145

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:d942c8692d257084abf3ac87279faff6

brief summary [clinicaltrials_vocabulary:brief-summary]

Cytomegalovirus (CMV) i ...... damage in people with HIV.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIV

http://www.w3.org/2001/XMLSchema#string

completion date [clinicaltrials_vocabulary:completion-date]

2006-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

detailed description [clinicaltrials_vocabulary:detailed-description]

CMV infection, most com ...... ganciclovir daily thereafter.

http://www.w3.org/2001/XMLSchema#string

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00006145 [clinicaltrials_resource:2a4f8214c386f2797af19b39175bfb00]

enrollment [clinicaltrials_vocabulary:enrollment]

350

http://www.w3.org/2001/XMLSchema#integer

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2000-08-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

intervention [clinicaltrials_vocabulary:intervention]

Valganciclovir [clinicaltrials_resource:b4088c7e89a8d0af9cd67a23502548be]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Valganciclovir [clinicaltrials_resource:3c4b31b67e867237cb00f74e7ea12bcc]

Ganciclovir [clinicaltrials_resource:faf30abfb2b4016270fc4af04ccddf26]

keyword [clinicaltrials_vocabulary:keyword]

Administration, Oral

http://www.w3.org/2001/XMLSchema#string

Antiviral Agents

http://www.w3.org/2001/XMLSchema#string

Cytomegalovirus Infections

http://www.w3.org/2001/XMLSchema#string

Cytomegalovirus

http://www.w3.org/2001/XMLSchema#string

DNA, Viral

http://www.w3.org/2001/XMLSchema#string

Ganciclovir

http://www.w3.org/2001/XMLSchema#string

Polymerase Chain Reaction

http://www.w3.org/2001/XMLSchema#string

Viremia

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2013-07-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

National Institute of Allergy and Infectious Diseases (NIAID) [clinicaltrials_resource:d9a74aeb9c0d0448f38e08189395de72]

link [clinicaltrials_vocabulary:link]

Haga clic aquí para ver información sobre este ensayo clínico en español. [clinicaltrials_resource:181cbc197a909f24cde435168f5102fe]

Click here for more information about valganciclovir hydrochloride [clinicaltrials_resource:fd5302e83fc67d8c14418bb457ddf713]

location [clinicaltrials_vocabulary:location]

Alabama Therapeutics CRS [clinicaltrials_resource:1f62951caa980784d48f1b5ac328dfb4]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00006145

http://www.w3.org/2001/XMLSchema#string

official title [clinicaltrials_vocabulary:official-title]

A Phase III, Prospective, Rand ...... ed by Plasma CMV DNA PCR Assay

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

A5030

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

Mark Jacobson, MD [clinicaltrials_resource:3a3cc532cb2866639c8def874cc61a12]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

United States: Food and Drug Administration [clinicaltrials_resource:77fa11db9aea1d8cd0ff35db5bc538f2]

phase [clinicaltrials_vocabulary:phase]

Phase 3 [clinicaltrials_resource:8357418e2694434468870b487644532d]

reference [clinicaltrials_vocabulary:reference]

11772283 [pubmed:11772283]

12022911 [pubmed:12022911]

12905142 [pubmed:12905142]

15125867 [pubmed:15125867]

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

secondary id [clinicaltrials_vocabulary:secondary-id]

10.170

http://www.w3.org/2001/XMLSchema#integer

source [clinicaltrials_vocabulary:source]

National Institute of Allergy and Infectious Diseases (NIAID) [clinicaltrials_resource:d9a74aeb9c0d0448f38e08189395de72]

start date [clinicaltrials_vocabulary:start-date]

2000-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00006145 study design [clinicaltrials_resource:df14943c416c29d81defd61281f0045d]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00006145

verification date [clinicaltrials_vocabulary:verification-date]

2013-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00006145

http://www.w3.org/2001/XMLSchema#string

title

Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIV

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Preventing Cytomegalovirus (CM ...... V [clinicaltrials:NCT00006145]

@en